B7-H4: a promising target for effector-enhanced drug modalities – a pipeline review

STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-B7-H4 immunotherapeutics in R&D: Pipeline of B7-H4-Targeted Immunotherapies.

This competitive intelligence report about B7-H4-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting B7-H4. This report will be prepared on demand within one working day upon order placement. The report lists B7-H4-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of B7-H4-targeted immunotherapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

The B7-H4 surface antigen is overexpressed in ovarian and endometrial cancers and is often associated with poor prognosis. B7-H4 is a member of the B7 family of immune checkpoint ligands and has been shown to negatively regulate T-cell function. B7-H4 binds to an unknown receptor on T cells and inhibits T-cell proliferation and cytokine production. B7-H4 expression is elevated across a broad range of solid tumors, including ovarian cancer, breast cancer, endometrial carcinoma, cholangiocarcinoma and gallbladder carcinoma, and squamous non-small cell lung cancer tumors. B7-H4 expression is limited in normal tissue, specifically immune cells, making it an ideal molecular target.

A number or antibody modality technologies were used to generate anti-B7-H4 drug candidates undergoing preclinical and clinical development, including antibody-drug conjugates, conditionally activated antibodies, T-cell engaging bispecific antibodies and other effector-enhanced antibody molecules.

The report “Pipeline of B7-H4-Targeted Immunotherapies” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pipeline-of-b7-h4-targeted-immunotherapies/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

SOURCE: La Merie Publishing